Clinical trials
Cisplatin clinical trials
Below are recruiting cisplatin clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06341764RecruitingPhase 2
Chemo-immunotherapy before surgery for bile duct cancer
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
Naples, ItaliaAges 18 years+ - NCT07662395RecruitingPhase 2/Phase 3
New drug plus chemo for advanced squamous lung cancer
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Guangzhou, GuangdongAges 18 years+ - NCT04447352RecruitingPhase 3
HIPEC plus FLOT versus FLOT alone for gastric or GE junction cancer
This trial compares two treatment approaches after your stomach/GE junction cancer has been treated with chemotherapy before surgery: adding a special heated bath into the abdomen (HIPEC) plus continuing the usual surgery plan. It aims to see if adding HIPEC lowers cancer coming back and improves outcomes.
AachenAges 18–75 - NCT07647289RecruitingPhase 2
Immunotherapy plus chemotherapy before bladder cancer surgery
This trial tests a combination of two drugs (eribulin and toripalimab) given before surgery to remove bladder cancer. The goal is to shrink the tumor and improve outcomes for people with advanced or high-risk bladder cancer.
Beijing, Beijing MunicipalityAges 18–80 - NCT07646301RecruitingPhase 2
Immune therapy with chemotherapy for advanced cervical cancer
This trial tests two immune-boosting drugs (iparomlimab and tuvonralimab) combined with standard chemotherapy given before surgery for locally advanced cervical cancer. The goal is to shrink the cancer and improve survival chances.
Guangzhou, GuangdongAges 18–70 - NCT05919030RecruitingPhase 3
Tislelizumab with chemoradiation for advanced esophagus cancer
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
Wuhan, HubeiAges 18 years+ - NCT07642024RecruitingPhase 2/Phase 3
BL-B01D1 Plus Osimertinib Before Surgery for EGFR-Mutated Lung Cancer
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07638852RecruitingPhase 2
Combining radiation and targeted drugs for triple-negative breast cancer brain tumors
This trial is testing whether giving radiation therapy along with a combination of chemotherapy (cisplatin or carboplatin), an immunotherapy drug called adebrelimab, and a drug called bevacizumab can better treat triple-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink or control the brain tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07640048Recruiting
Adjuvant therapy after surgery for high-risk bile duct cancer
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
BeijingAges 18 years+ - NCT06690476RecruitingEarly Phase 1
Study of IPM514 for esophageal cancer
This trial tests a new drug called IPM514 for people with a type of esophageal cancer (squamous cell). It aims to find out if the drug is safe and effective. The trial has different groups for those who have had prior treatment and those who will have surgery after treatment.
BeijingAges 18 years+ - NCT03480971RecruitingPhase 2
Tempol to reduce mouth and other side effects from radiation and cisplatin
This Phase 2 trial tests tempol to lessen harmful side effects caused by head-and-neck radiation and the chemotherapy drug cisplatin. If you qualify, you may receive tempol during treatment to help protect normal tissues and reduce toxicity.
La Jolla, CaliforniaAges 18 years+ - NCT07622186RecruitingPhase 2
SKB571 combination therapy for advanced lung cancer
This trial tests a new drug called SKB571, given in combination with other treatments, for non-small cell lung cancer (a common type of lung cancer). The study aims to see if this combination helps shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT06696742RecruitingPhase 2
PD-1 inhibitor plus probiotic for bladder cancer
This trial tests a combination of a PD-1 inhibitor (which helps your immune system fight cancer) and a probiotic called Clostridium butyricum for people with bladder cancer. It is for those who either have invasive bladder cancer before surgery, or have high-risk features after surgery, and haven't had previous immunotherapy or chemotherapy.
Nanjing, JiangsuAges 18 years+ - NCT07619313RecruitingPhase 1
AB801 with Chemotherapy and Immunotherapy for Bile Duct or Pancreatic Cancer
This study tests a new drug called AB801 combined with standard chemotherapy and immunotherapy for advanced bile duct cancer (cholangiocarcinoma) or pancreatic cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
Los Angeles, CaliforniaAges 18 years+ - NCT07619235RecruitingPhase 4
Combination immunotherapy and chemotherapy for advanced bile duct cancer
This study tests a combination of four drugs—two immunotherapy drugs (iparomlimab and toripalimab), a targeted therapy (bevacizumab), and chemotherapy—as a first-line treatment for advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to see if this combination can shrink tumors and help patients live longer.
Wuhan, HubeiAges 18–75 - NCT07601737RecruitingPhase 2
Nimotuzumab with immunotherapy and chemotherapy for head and neck cancer
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
ShanghaiAges 18–75 - NCT06718205RecruitingPhase 2
Nimotuzumab plus immunotherapy and chemo for esophageal cancer
This study tests a new combination of drugs for advanced esophageal cancer. It adds an antibody (nimotuzumab) and an immunotherapy (sintilimab) to standard chemotherapy, aiming to improve how well treatment works.
Zhengzhou, HenanAges 18–75 - NCT07583550RecruitingPhase 2
Low-dose radiation followed by immunotherapy for extensive small cell lung cancer
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
Jiangmen, GuangdongAges 18–75 - NCT06725498RecruitingPhase 2
Chemo, radiation, and immunotherapy for advanced head and neck cancer
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07570849RecruitingPhase 2
Chidamide with chemotherapy and immunotherapy for advanced bile duct cancer
This trial tests a combination of three treatments—chidamide (a new type of cancer drug), chemotherapy, and immunotherapy—for advanced intrahepatic cholangiocarcinoma (a cancer of the bile ducts inside the liver). The goal is to see if this combination can shrink tumors and help patients live longer when used as a first treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07569679RecruitingPhase 2
Combination Chemotherapy and Immunotherapy for Biliary Tract Cancer
This trial tests a combination of chemotherapy drugs given directly into the liver, combined with two immunotherapy/targeted therapy drugs, for people with advanced biliary tract cancer (cancer of the bile ducts or gallbladder). The goal is to shrink tumors and improve survival in patients who have not received prior chemotherapy.
Xi'an, ShaanxiAges 18 years+ - NCT04278287RecruitingPhase 1/Phase 2
Chemoradiation study for unresectable esophageal cancer
This Phase 1/2 trial tests a treatment plan using chemotherapy plus radiation for esophageal squamous cell cancer that cannot be removed with surgery. It may help shrink or control the cancer and guide safer dosing, but it’s only for people with specific tumor stage, health status, and blood test results.
Anyang, HenanAges 18–75 - NCT07559929RecruitingPhase 1/Phase 2
DXC006 with immunotherapy or chemotherapy for small cell lung cancer
This trial tests a new drug called DXC006, combined with either immunotherapy (checkpoint inhibitors) or platinum-based chemotherapy, for patients with small cell lung cancer. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07566156RecruitingPhase 3
New drug combination vs. radiation for bladder cancer preservation
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
Santa Barbara, CaliforniaAges 18 years+
Hear when a new Cisplatin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cisplatin?
- Yes. Clin2 currently lists 484 recruiting cisplatin studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cisplatin trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cisplatin trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.